Jeff Thompson, President, CEO, & Chairman
Jeffery S. Thompson is a Partner with Tampa, Florida based HealthEdge Investment Partners, LLC, an operating-oriented private equity firm founded in 2005 that provides strategic capital exclusively in the healthcare industry.
Mr. Thompson currently serves as President, CEO, and Chairman of Enaltus, a Suwanee, Georgia based HealthEdge portfolio company specializing in unique skincare solution with direct operations in the US and global distribution partnerships.
Mr. Thompson serves as an Independent Director and Compensation Committee Member with the Board of Directors for Anika Therapeutics, Inc., a publicly traded Bedford, Massachusetts based biotechnology company that develops, manufactures and commercializes therapeutic hylauronic acid based products for tissue protection, healing, repair and regeneration. Mr. Thompson serves as a Director for Inifinity HomeCare, a privately held Florida based home health care provider that focuses on providing patients the highest level of Medicare covered services and therapy available through quality personnel, educational training, and specialty home health care programs.
Mr. Thompson serves as a Director for Advanced Bio-Technologies, Inc. (ABT) a wholly owned subsiduary of Sinclair Pharma, PLC, a publicly traded UK based skincare company, which purchased ABT from HealthEdge and other shareholders while Mr. Thompson served as President, CEO and Chairman. Prior to the strategic sale, ABT focused on the treatment and management of scars with unique patent protected silicone products based on cross-linking technologies marketed under the brands Kelo-cote® and bioCorneum+® through direct operations in the United States and in over 50 countries throughout the world via a network of local marketing partners. Mr. Thompson served as Chairman of Woodbury Products, Inc., an Oceanside, New York based HealthEdge portfolio company dedicated the distribution of high quality incontinence and related healthcare products which was sold to MTS Health Investors in March 2012.
Prior to joining HealthEdge, Mr. Thompson was a Director and the Chief Operating Officer for Stiefel Laboratories, Inc., the world’s largest independent pharmaceutical company specializing in dermatology. Mr. Thompson continued to serve as a member of Stiefel’s Board of Directors through the closing of Glaxo SmithKline’s acquisition of Stiefel in July of 2009. Prior to becoming Stiefel’s COO, Mr. Thompson served as Stiefel’s Senior Vice President U.S. Business Services and President of Glades Pharmaceuticals. During his tenure in this dual leadership role, Glades grew from $36 million to over $73 million.
Earlier in his career, Mr. Thompson held Sales and Business Management positions at Bausch & Lomb Pharmaceuticals and he began his career at SmithKline Beecham as a Professional Sales Representative.
Mr. Thompson received his Bachelor’s degree in General Science after completing one year of study in Dental Medicine, both at the University of Pittsburgh.
Zubin Meshginpoosh, Chief Operating Officer, EVP Professional
Mr. Meshginpoosh joins Advanced Bio-Technologies, Inc. with 8 years of pharmaceutical industry experience, in addition to 5 years of operations management experience with United Parcel Service. After leaving UPS, Mr. Meshginpoosh began his career in pharmaceuticals with Bayer Corporation as a field sales representative and later joined Salix Pharmaceuticals to help build their growing organization, and advanced in his areas of responsibility. Mr. Meshginpoosh left Salix to help start StoneBridge Pharma, a wholly-owned subsidiary of Stiefel Laboratories, Inc., as Gastrointestinal Marketing Manager. While at StoneBridge, he worked in several cross-functional roles including Business Development and Sales Training. Most recently, Meshginpoosh was with Inspire Pharmaceuticals where he served as Associate Director of Strategic Markets, Marketing and Analytics. Meshginpoosh received his Bachelor’s of Science in Science and Mathematics from Bowling Green State University, his M.B.A. in Marketing and International Management at the University of Toledo, and his Master’s of Science in Corporate Finance from Walsh College in Troy, Michigan.
Martin Floreani, Chief Marketing Officer, EVP International
Mr. Floreani has over fifteen years of management experience, four in consumer sales and marketing and eleven in the pharmaceutical industry with a large portion of his career being skincare. Martin began his career with The Andrew Jergens Company where he opened and managed a regional subsidiary that imported and manufactured skincare products in South America. Four years later, after growing the operation significantly at a retail level, he took a regional marketing position with Merck & Co (MSD) in Miami. In this role he was responsible for a much larger region in Latin America and launched Propecia®, a prescribed dermatological hair-loss product for men which today represents approximately $400 million.
Martin also worked as an Office-base Professional Field Sales Representative in New York City where he spent thirty months promoting blockbuster products across different specialties and disease categories such as asthma, cardiovascular, pain/arthritis, and osteoporosis and was awarded many of the company’s highest ranked sales achievements. His achievements resulted in a Global Product Management assignment for Merck’s respiratory division in the New Jersey headquarters as part of a team that managed the marketing strategy for a $US2.5 billion franchise.
In 2004, Martin was approached with the opportunity to build and lead a global marketing function at Stiefel laboratories, based in Coral Gables, Florida. Over the next five years he would hold various key roles at Stiefel in marketing and strategy and develop valuable experience in planning, corporate development (particularly M&A), restructuring, and leadership. In July, 2009, Stiefel was acquired by GlaxoSmithKline for $US 3.6 billion, a transaction in which he played a key role as VP of Global Strategy and as part of the company’s core management team. Upon completion of the transaction Martin joined Advanced Bio-Technologies in his current role with P&L responsibility for International. Martin has an MBA in Finance and a BBA in International Finance and Marketing from the University of Miami.
Enaltus Medical, Clinical and Regulatory Support
Mercedes Florez, MD PhD, MBA, Medical Consultant
Dr. Florez is a practicing physician with more than 25 years of experience in clinical and aesthetic dermatology, in academic and private practice, as well as in the pharmaceutical industry. Her breadth and depth of knowledge and experience is an invaluable asset to the companies she provides consulting services. Dr. Florez’ clinical and cosmetic experience began in 1984 as a solo practice in Colombia. In 1996 she became Director of one of Colombia’s major dermatology clinics, and in 1999 Dr. Florez relocated to Miami as Director of Cosmetic Services for the Greater Miami Skin and Laser Center. While in this position, she planned and created the cosmetic center and where she continues to practice to date.
Dr. Florez’ industry experience is equally impressive, having worked as an investigator, consultant and speaker with Schering, Novartis and Galderma from 1989 to 2001. More recently, she was Sr. Director of Medical and Scientific Affairs for Stiefel Laboratories from 2005 to 2009 where she structured, created and managed every function of that team for Latin America and the Caribbean. Fluent in Spanish, Portuguese and English, Dr. Florez presents regularly at major medical congresses and symposia around the world and consults for multiple specialty dermatology companies.
Dr. Florez completed her PhD and residency in dermatology at the University of Sao Paolo in Brazil, and her doctorate in medicine and surgery at Javeriana University School of Medicine in Bogota, Colombia. Driven by her entrepreneurial spirit and business acumen, Dr. Florez also earned an MBA with a specialization in Administration and Management of Medical Centers.
Tanya Rhodes, PhD, Consulting VP Regulatory & Technical Affairs
Dr. Rhodes is a consultant to the wound and skin care industry providing services in everything from R&D though new business ventures. In addition to her role with Enaltus, she is currently acting Chief Technology Officer for a start up pharmaceutical company specializing in NO (Nitrous Oxide) for chronic wound care; a Regulatory and Clinical Consultant for a small dermatological company commercializing a class II injectable device; a Regulatory and Clinical Consultant for an ophthalmology company developing new drug (NDA) for application of infections post eye surgery; and, a due diligence services specialist to numerous biotech and pharmaceutical companies. Previously she held President and General Management positions in both the Professional and Retail market sectors bringing forward new innovations and drug device combinations from concept to commercialization.
Dr. Rhodes entrepreneurial spirit started in 1992 when she was asked to relocate to the US to start a new R&D group for Smith & Nephew. Under her guidance the group expanded to include Strategic Marketing; Business Development; Medical / Science Liaison; Legal; Clinical Research and Technical Service. As part of the senior management team, she helped grow the US business from $50M to $160M before joining the Viasys Group as President of the New Technologies Division. This division was finally spun out as a new start up company specializing in NO (mentioned above). Ms. Rhodes has a Masters Degree with a major in Technology Management from the University of Miami and graduated with honors in Chemistry from Hull University, England. Tanya also completed the full research for her PhD in Computational Stereochemistry before relocating to the US.